PFVN

ProFound Therapeutics is a clinical-stage biotechnology company pioneering the exploration of the "expanded human proteome" to discover novel protein-coding genes and therapeutic targets. Founded by Flagship Pioneering, the company utilizes its proprietary ProFoundry Platform, which integrates high-throughput protein discovery, functional validation, and advanced computational tools to identify tens of thousands of previously unannotated proteins. These novel proteins, often referred to as "proteomic dark matter," serve as the basis for developing first-in-class medicines across diverse therapeutic areas, including cardiovascular disease, obesity, and oncology. ProFound has established significant strategic collaborations with industry leaders such as Novartis and Pfizer to accelerate the development of its discovery-stage programs.